Fixing Drug Pricing? Congress Enacts Generic Inflation Rebate And Turns Up Heat On FDA
This article was originally published in RPM Report
Executive Summary
Amid a storm of controversy about “re-pricing” of older brands, the US Congress has reacted in two seemingly contradictory ways. First, new legislation creates what amounts to a tax on generic drug companies who raise prices. At the same time, legislators are eager to press FDA to move faster on generic drug approvals to assure competition for high priced brands.
You may also be interested in...
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
GDUFA II Negotiations: Let the Saber-Rattling Begin
The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.